Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

20212,395 citationsJournal Articlegreen Open Access

Authors

Oliver Sartor · Tulane University

Johann S. de Bono · Cornell University

Kim N. · BC Cancer Agency

Karim Fizazi · Cornell University

Ken Herrmann · Cornell University

Kambiz Rahbar · Cornell University

Scott T. Tagawa · Cornell University

Abstract

Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. Lutetium-177 (177Lu)–PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Mass Spectrometry Techniques and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 385, Issue 12, pp. 1091-1103

DOI: 10.1056/nejmoa2107322

Field-Weighted Citation Impact: 236.84